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Abstract As the aging of the population advances, the
use of nonsteroidal anti-inflammatory drugs (NSAIDs) and/
or low-dose aspirin (LDA) is increasing. Their use is
accompanied by a risk of serious complications, such as
hemorrhage or perforation of the gastrointestinal tract.
Therefore, gastroprotective strategies upon the prescription
of NSAIDs/LDA are outlined in several guidelines or
recommendations. Because all NSAIDs including cyclo-
oxygenase (COX)-2 inhibitors have cardiovascular (CV)
toxicity, recent guidelines are based on not only GI risks
but also CV risks of NSAID users. Assessment of the
adherence to evidence-based guidelines or recommenda-
tions for the safe prescription of NSAIDs/LDA in clinical
practice is an important issue. Here, we summarize ran-
domized controlled trials (RCTs) on the preventive effects
of antisecretory drugs for NSAID- or LDA-induced peptic
ulcers. Then, we describe preventive strategies upon the
prescription of NSAIDs/LDA outlined in several guidelines
or recommendations, and describe studies on adherence
and outcomes of adherence to these preventive strategies.
Finally, we discuss strategies to increase the adherence
rate, and changing pattern of GI events associated with
NSAIDs/LDA. In Japan, the preventive strategies upon the
prescription of NSAIDs/LDA are expected to spread rap-
idly because the use of proton pump inhibitors for the
prevention of recurrence of NSAID- or LDA-induced
peptic ulcers and the use of COX-2 for the palliation of
acute pain were recently approved under the national health
insurance system. Further studies on adherence to the
preventive strategies and the outcomes of adherence, which
include both GI events and CV events, in the Japanese
population are required.
Keywords Adherence  Preventive strategy 
Nonsteroidal anti-inflammatory drug  Low-dose aspirin 
Gastrointestinal injury
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of
the medicines most frequently prescribed in regular prac-
tice, and are used for the suppression of fever, pain, and
inflammation in various acute and chronic diseases, such as
headache, musculoskeletal pain, osteoarthritis, and rheu-
matoid arthritis. Low-dose aspirin (LDA), which is another
of the most frequently prescribed medicines, is used for
secondary prevention of ischemic heart disease and cere-
brovascular disease. As the aging of the population
advances, the number of patients with chronic pain, car-
diovascular disease, or cerebrovascular disease is increas-
ing, as is the number of prescriptions of NSAIDs and/or
LDA.
However, it is well known that NSAIDs and LDA cause
gastrointestinal mucosal injuries, and the prescriptions of
NSAIDs and LDA are accompanied by the risk of serious
complications, such as hemorrhage or perforation of the
gastrointestinal tract. NSAID/LDA-induced gastrointesti-
nal injuries are not often associated with gastrointesti-
nal symptoms, whereas gastrointestinal symptoms often
develop without mucosal injury in NSAID/LDA users. The
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first sign of NSAID/LDA-induced gastrointestinal injuries
in asymptomatic individuals may be a life-threatening
complication [1]. In addition, it is reported that NSAID-
and LDA-induced hemorrhagic ulcers often require addi-
tional endoscopic hemostasis treatment, and their treatment
is more difficult [2].
Upon the prescription of NSAIDs, gastroprotective
strategies are outlined in several guidelines considering
gastrointestinal (GI) risk factors that were identified in
observational studies. Because it was found that NSAIDs
including cyclooxygenase (COX)-2 inhibitors have car-
diovascular (CV) toxicity, recent guidelines were devel-
oped on the basis of not only GI risks but also CV risks of
NSAID users [3–6].
In Japan, guidelines for gastric ulcers were published in
2003, and were revised in 2007 [7]. In addition, peptic
ulcer practice guidelines were published by the Japanese
Society of Gastroenterology in 2009 [8]. In these guide-
lines, NSAID users with advanced age and/or peptic ulcer
history were considered as high-GI-risk patients, and pro-
ton pump inhibitor (PPI) or prostaglandin analogue (PA)
therapy is recommended for them for the prevention of
NSAID-induced GI injury. In Japan, however, until the use
of lansoprazole at 15 mg was approved for the prevention
of recurrence of NSAID- or LDA-induced peptic ulcers in
July 2010, the practice outlined in the guidelines could not
be provided under the national health insurance system. In
addition, PA or high-dose histamine type 2-receptor
antagonist (H2RA) therapy is not presently approved for
the prevention of NSAID-induced peptic ulcers under the
health insurance system in Japan.
The use of COX-2 inhibitors, which can decrease GI
toxicity associated with nonselective COX inhibition, is a
different strategy from the use of gastroprotective agents
for high-GI-risk NSAID users. In Japan, however, the use
of celecoxib under the health insurance system had been
limited until the indication of celecoxib use was approved
in the palliation of acute pain in December 2011.
Recently, reports based on studies of the adherence to
preventive strategies for NSAID- or LDA-induced gastro-
intestinal injury have been accumulating [9–20]. In this
review, we focus on the adherence to the preventive
strategies for NSAID/LDA-induced gastrointestinal inju-
ries, and the outcome of such adherence.
Preventive effects of PPIs for NSAID-induced peptic
ulcers in at-risk patients
A summary of randomized controlled trials (RCTs) on the
preventive effects of PPIs for NSAID-induced peptic ulcers
in at-risk patients is shown in Table 1. Two studies con-
ducted on patients with a history of peptic ulcers were
reported in Japan in 2012. Both low-dose lansoprazole [21]
and esomeprazole [22] were more effective than gefarnate
or placebo in reducing the risk of peptic ulcer recurrence,
and hazard ratios (HRs) of 0.2510 (95 % confidence
interval (CI) 0.1400–0.4499) and 0.09 (95 % CI 0.04–0.20)
were reported, respectively.
In a trial of esomeprazole that was conducted outside of
Japan, the estimated cumulative proportions of patients
developing peptic ulcer at 6 months were reported as
17.0 % (95 % CI 13.2–20.8) with placebo, 5.2 % (95 % CI
3.0–7.4) with esomeprazole at 20 mg, and 4.6 % (95 % CI
2.6–6.6) with esomeprazole at 40 mg in at-risk patients
using NSAIDs [23].
Chan et al. [24] reported that omeprazole was superior
to the eradication of Helicobacter pylori in preventing
recurrent upper GI bleeding in a 6-month treatment period
in patients who were taking naproxen (omeprazole 4.4 %
vs. placebo 24.4 %, p = 0.005). In addition, the efficacy of
lansoprazole in the prevention of peptic ulcer relapse after
eradication of Helicobacter pylori in naproxen users was
reported by Lai et al. At 8 weeks, significantly fewer
patients in the lansoprazole group (4.5 %) than in the group
with Helicobacter pylori eradication alone (42.9 %)
developed recurrence of ulcers [25].
Graham et al. conducted a study that compared PPI with
misoprostol in NSAID users without Helicobacter pylori
infection who had a history of gastric ulcer. The estimated
cumulative proportion of patients developing peptic ulcer
at 3 months was reported to be 53 % in the placebo group,
21 % in the group with lansoprazole at 15 mg, 17 % in the
group with lansoprazole at 30 mg, and 8 % in the group
with misoprostol, indicating that lansoprazole is effective
for the prevention of NSAID-induced peptic ulcers, but is
not superior to misoprostol. However, poor compliance due
to adverse events such as diarrhea was reported in the
misoprostol group [26].
There have been three studies that compared COX-2
inhibitor with PPI plus nonselective NSAIDs in a high-GI-
risk group with a history of bleeding peptic ulcer [27–29].
Chan et al. [27] reported that, in a 6-month treatment
period, the proportions of patients who developed upper GI
bleeding were 6.4 % in the omeprazole plus diclofenac
group and 4.9 % in the celecoxib group (p = 0.60). Lai
et al. [28] reported similar results using lansoprazole in a
6-month treatment period (lansoprazole plus naproxen
6.3 % vs. celecoxib 3.7 %, p = 0.37). Chan et al. [29] also
reported that the proportions of patients who developed peptic
ulcers confirmed by endoscopy at 6 months were 32.3 % in
the omeprazole plus diclofenac group and 24.1 % in the
celecoxib group (p = 0.15). These studies indicate that
COX-2 inhibitor is as effective as PPI co-therapy.
A trial that compared the effect of PPI plus COX-2
inhibitor with that of COX-2 inhibitor was reported in 2007
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in a high-GI-risk group with a history of bleeding peptic
ulcer. In a 3-month treatment period, significantly fewer
patients in the esomeprazole plus celecoxib group (0 %)
than in the celecoxib group (8.9 %) developed upper GI
bleeding events [30].
Preventive effects of antisecretory drugs
for LDA-induced peptic ulcers
A summary of RCT on the preventive effects of antise-
cretory drugs for LDA-induced peptic ulcers is shown in
Table 2. Three studies were conducted using PPIs (low-
dose lansoprazole, rabeprazole, and esomeprazole) in
patients with a history of peptic ulcers in Japan [31–33],
and two studies have so far been published [31, 33]. All of
low-dose lansoprazole, rabeprazole, and esomeprazole
were more effective than gefarnate or placebo in reducing
the risk of peptic ulcer recurrence, and HRs were reported
to be 0.099 (95 % CI 0.042–0.230), 0.179 (95 % CI
0.082–0.394), and 0.09 (95 % CI 0.02–0.41), respectively.
In the trial of rabeprazole, the cumulative rate of ulcer
recurrence at 12 weeks in the rabeprazole 20 mg group
(3.7 %) was lower than that in the rabeprazole 10 mg
group (7.4 %), although there was no significant difference
between them [33].
Two trials of esomeprazole were conducted outside of
Japan on at-risk patients using LDA, and significant risk
reductions of ulcer development were reported in 2008 and
2011 [34, 35]. Two doses of esomeprazole were used in the
trial of 2011, but a dose-dependent preventive effect was
not identified [35].
Taha et al. reported the efficacy of a normal dose of
H2RA for the prevention of peptic ulcers and esophagitis in
LDA users. At 3 months, the proportions of patients who
developed gastric ulcers were 3.4 % in the famotidine
40 mg group and 15.0 % in the placebo group (HR 0.20,
95 % CI 0.09–0.47). In addition, the proportions of patients
who developed duodenal ulcers were 0.5 % in the famo-
tidine 40 mg group and 8.5 % in the placebo group (HR
0.05, 95 % CI 0.01–0.40) [36].
Chan et al. [24] reported that omeprazole was not
statistically superior to the eradication of Helicobacter
pylori in preventing recurrent upper GI bleeding in a
6-month treatment period in LDA users (omeprazole
0.9 % vs. placebo 1.9 %). However, the efficacy of lan-
soprazole in the prevention of peptic ulcer relapse after
eradication of Helicobacter pylori in LDA users was
reported by Lai et al. in 2002. In a 12-month treatment
period, significantly fewer patients in the lansoprazole
group (1.6 %) than in the group with Helicobacter pylori
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Ng et al. [38, 39] reported two trials that compared the
effect of PPI with that of H2RA for the prevention of upper
GI complications in LDA users. In a trial reported in 2010,
the effect of pantoprazole at 20 mg was compared with that
of high-dose famotidine (80 mg) in LDA users with a
history of upper GI bleeding or dyspepsia due to peptic
ulcer/erosion. In a 12-month treatment period, significantly
fewer patients in the pantoprazole group (0 %) than in the
famotidine group (20 %) developed dyspeptic or bleeding
ulcer/erosion [38]. Furthermore, in another trial reported in
2012, the effect of esomeprazole at 20 mg was compared
with that of famotidine at 40 mg in patients with acute
coronary syndrome or ST elevation myocardial infarction
receiving a combination of aspirin, clopidogrel, and either
enoxaparin or thrombolytics. In a mean follow-up period
of approximately 5 months, 0.6 % of patients in the
esomeprazole group and 6.1 % of patients in the famoti-
dine group developed upper GI bleeding, perforation, or
obstruction from ulcer/erosion (HR 0.095, 95 % CI
0.005–0.504) [39].
Bhatt et al. also reported the preventive effect of PPI for
GI events in patients receiving dual antiplatelet therapy
(aspirin plus clopidogrel). At 6 months, the gastrointestinal
event rates were 1.1 % with omeprazole and 2.9 % with
placebo (HR 0.34, 95 % CI 0.18–0.63) [40].
Definitions of high-risk NSAID users and recommended
preventive strategies in recent guidelines
The definitions of GI risk and CV risk and recommended
preventive strategies in recent guidelines on NSAID
therapy are shown in Table 3. A history of peptic ulcer
complication, a history of peptic ulcer disease, advanced
age, concomitant use of anticoagulants, concomitant use
of aspirin, concomitant use of corticosteroid, and high-
dose NSAIDs are consistently considered as definite GI
risk factors in the guidelines. Helicobacter pylori infec-
tion, concomitant use of selective serotonin reuptake
inhibitors, and concomitant use of bisphosphonate are
also identified as GI risk factors in some observational
studies [4, 5]. Lanza et al. [5] recently reported guidelines
that stratified the GI risk into low- (no risk factors),
moderate- (1-2 risk factors), and high-risk groups [mul-
tiple (C3) risk factors, or a history of peptic ulcer com-
plications, or concomitant use of corticosteroids or
anticoagulants] by the type and number of risk factors.
The use of COX-2 plus PPI/misoprostol is consistently
recommended for high-GI-risk patients in guidelines,
although misoprostol is not recommended, owing to the
occurrence of GI side effects [43], in several guidelines
[4, 6].
High CV risk is defined as the requirement for LDA for
prevention of serious CV events. In several guidelines, an
estimated 10-year risk of a fatal CV event of more than
10 % or more than 20 % in patients without established
CV disease is considered as a high CV risk [3, 6].
Both COX-2 inhibitors and nonselective NSAIDs share
similar CV risks, with an increase in acute myocardial
infarction, congestive heart failure, and sudden death [1].
In a recent review on the cardiovascular risk associated
with NSAIDs, however, it was suggested that naproxen and
low-dose ibuprofen are least likely to increase cardiovas-
cular risk [41]. Therefore, the use of naproxen as an
NSAID is consistently recommended for high-CV-risk
patients in guidelines.
Adherence to evidence-based guidelines for the safe
prescription of NSAIDs
Assessment of the adherence to evidence-based guidelines
for the safe prescription of NSAIDs in clinical practice is
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adherence to preventive strategies for NSAID-induced
gastrointestinal injury is shown in Table 4.
In two retrospective cross-sectional studies in the USA,
which were conducted on 76,765 NSAID users from the
database of the Tennessee Medicaid program and 707,244
NSAID users from the database of Veterans Affairs, it was
shown that the rate of adherence to preventive strategies for
NSAID-induced gastrointestinal injury was low [9, 10].
Smalley et al. [9] reported that the proportions of patients
who received gastroprotective therapy recommended in the
guidelines were 18 % in the NSAID users with a single GI
risk factor and 30 % in the NSAID users with two or more
GI risk factors. Abraham et al. reported that the rates of
adherence to preventive strategies were 27.2 % in the
NSAID users with at least 1 GI risk factor, 39.7 % in those
with at least 2 GI risk factors, and 41.8 % in those with at
least 3 GI risk factors. In addition, it was reported that
NSAID prescription C90 days was a predictor of non-
adherence [10].
In the Netherlands, a similar retrospective study on
50,126 NSAID users from the Integrated Primary Care
Information database was carried out. In that study,
although 43.3 % of NSAID users had GI-associated risk,
the rate of adherence to preventive strategies was reported
to be 21.9 % in high-risk NSAID users. This rate rose from
6.9 % in 1996 to 39.4 % in 2006 in high-risk NSAID users,
but was still at a low level [11].
Recently, a prospective cross-sectional observational
study that evaluated both GI risk and CV history in 17,105
osteoarthritis (OA) patients who visited 1,760 doctors
throughout the Spanish National Health System in a single
day was conducted [12]. Among these OA patients, 93.4 %
had more than one GI risk factor, 60.3 % were in the high-
GI-risk group, and 32 % had a CV history. Approximately
four-fifths of patients received NSAID therapy. Although
25.3 % had both high GI risk and CV history, 74.4 % of
this subpopulation received nonselective NSAIDs (94.5 %
of them also received gastroprotective agents) or COX-2
inhibitors (82.4 % of them also received gastroprotective
agents), which are prescriptions that should be avoided
according to the guidelines. In addition, 61.8 % of patients
with high GI risk and no CV history were treated with
COX-2 inhibitors alone or nonselective NSAIDs plus PPI,
although the use of COX-2 inhibitors plus PPI is recom-
mended for those patients in the guidelines. These data
suggest that assessments of CV risk and stratified GI risk
are not fully implemented in routine clinical practice, and
show the difficulty in translating guidelines into clinical
practice [12].
On the other hand, over-prescription of PPI and/or
COX-2 inhibitors in patients with no risk factors was
indicated in studies in both the Netherlands and Spain [11,
12].
Outcomes of adherence to preventive strategies
for the safe prescription of NSAIDs
A summary of several recent studies on the outcomes of
adherence to preventive strategies for NSAID-induced GI
injury is shown in Table 5. Goldstein et al. conducted a
retrospective cross-sectional study using a managed-care
database in the USA. Of 2,634 NSAID users (nonselective
NSAIDs 1,312, COX-2 inhibitors 1,322) receiving con-
comitant PPI or H2RA therapy, 463 NSAIDs users (non-
selective NSAIDs 161, COX-2 inhibitors 302) developed
upper-GI events (peptic ulcer and/or bleeding). Of NSAID
users receiving concomitant PPI therapy, 68 % had a PPI
coverage rate of 80 % or more over the course of NSAID
treatment. A significantly higher risk of upper-GI events
was observed in nonselective NSAID users with a PPI
coverage rate of less than 80 % than in those with a PPI
coverage rate of 80 % or more (OR 2.4, 95 % CI 1.0–5.6),
but no such relationship was observed in COX-2 inhibitor
users [13].
Abraham et al. conducted a retrospective cohort study to
examine the effect of PPI gastroprotection on the risk of
NSAID-related upper-GI events in 481,980 NSAID users
in the Veterans Affairs database. In that cohort, PPIs were
co-prescribed for 19.8 %, and 2,753 upper-GI events
occurred in 220,662 person-years of follow-up. HR (95 %
CI) of upper-GI events on traditional NSAIDs alone, coxib
alone, traditional NSAIDs plus PPI, and coxib plus PPI
were estimated to be 1.8 (1.6–2.0), 1.8 (1.5–2.0), 1.1
(0.7–4.6), and 1.1 (0.6–5.2), respectively. In addition, an
inverse relationship between PPI coverage rate and HR of
upper-GI events was reported [15]. Moreover, Abraham
et al. reported a retrospective cohort study of 3,566 NSAID
users who had suffered an NSAID-related upper-GI event
by using the Veterans Affairs database. Hospitalization
occurred in 47.5 % of that cohort, and PPI therapy was
associated with a 30 % reduction in hospitalization com-
pared with that in those with no PPI. As a result, although it
was associated with higher pharmacy costs, a substantial
reduction of five-year medical costs was observed with PPI
therapy [17].
Van Soest et al. conducted a nested case–control study
by using the Integrated Primary Care Information database
in the Netherlands, and reported a strong inverse relation-
ship between the gastroprotective agent coverage rate over
the course of NSAID treatment and the risk of upper-GI
complications (symptomatic upper-GI ulcer and/or upper-
GI bleeding/perforation) in high-GI-risk NSAID users.
Compared with NSAID users with a gastroprotective agent
coverage rate of C80 %, NSAID users with gastroprotec-
tive agent coverage rates of 20–80 % and of \20 % had
2.5-fold and 4.0-fold increased risks of upper-GI compli-
cations, respectively [14]. Moreover, van Soest et al. [18]
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conducted a similar nested case–control study by using
three European databases (from the UK, the Netherlands,
and Italy), and a similar relationship between gastropro-
tective agent coverage rate over the course of NSAID
treatment and the risk of upper-GI events was identified.
To date, no large-scale observational studies on the
outcomes of adherence to preventive strategies for NSAID-
induced GI injury have been reported in Japan. In a ret-
rospective study by Tsumura et al. [16], however, the
association between adherence to guidelines for safe pre-
scription of NSAIDs and the incidence of gastric mucosal
lesions in NSAID users who had undergone endoscopy was
examined, and it was reported that gastric ulcers were more
frequently observed in the non-adherence group than in the
adherence group (29.6 vs. 4.0 %).
Recommended preventive strategies in at-risk LDA
users
The use of LDA for cardioprophylaxis is associated with a
2- to 4-fold increase in the risk of an upper-GI event [42].
As for LDA-induced GI injury, similar factors identified
for NSAID-induced GI injury have been suggested as GI
risk factors in LDA users [43], although there have been far
fewer studies on the risk of LDA therapy. In the ACCF/
ACG/AHA 2008 expert consensus document, a history of
peptic ulcer complication, a history of peptic ulcer disease,
GI bleeding, dual antiplatelet therapy, concomitant use of
anticoagulant, concomitant use of corticosteroid, age C60,
and dyspepsia/gastroesophageal reflux disease (GERD)
symptoms were considered as risk factors in LDA users,
and PPI therapy was recommended for the prevention of
LDA-induced GI injury in at-risk LDA users [42]. Before
starting chronic LDA therapy, testing for and eradicating
Helicobacter pylori in patients with a history of ulcer
disease is also recommended [42].
Outcomes of recommended preventive strategies
in at-risk LDA users
Regarding the outcomes of preventive strategies in at-risk
LDA users, only a few studies have so far been carried out.
Ng et al. conducted a retrospective cohort study on the
effect of treatment with antisecretory agents for upper-
gastrointestinal bleeding in 987 patients with LDA and
clopidogrel co-therapy. The risk of upper-GI bleeding was
reported to be marginally reduced by H2RA (OR 0.43,
95 % CI 0.18–0.91) and significantly reduced by PPI (OR
0.04, 95 % CI 0.002–0.21), compared with that in a control
group [19]. In addition, Hsiao et al. conducted a popula-
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users (12,001 LDA users, 2,627 clopidogrel users) who had
a history of hospitalization for GI complications before the
initiation of antiplatelet therapy using the Taiwanese
National Health Insurance database. The incidences of
recurrent hospitalization for major GI complications were
reported to be 0.125 per person-year in LDA users and
0.103 per person-year in LDA plus PPI users (HR 0.76,
95 % CI 0.64–0.91), indicating a significant preventive
effect of PPI [20].
Strategies to increase adherence rate
Education for physicians is important to raise the rate of
adherence to preventive strategies for NSAID/LDA-induced
GI injuries. Laine et al. [44] reported the efficacy of an inter-
vention using a written reminder and required written response
regarding preventive strategies in NSAID users. After the
intervention, the rate of adherence to preventive strategies was
improved from 43 to 61 % in NSAID users with GI risk.
Among the patients who were not provided gastroprotective
agents, however, 42 % of patients did not wish to take them,
which indicates that education for patients is also important.
Lanas et al. conducted a prospective, observational, lon-
gitudinal study of 1,232 NSAID users with GI-related risk
who were co-prescribed NSAID and gastroprotective agents
for at least 15 days, and investigated adherence to these agents
by telephone interviews. In terms of the reasons for non-
adherence to these agents, patients most frequently cited for-
getfulness [46]. Taking of NSAIDs/LDA does not necessarily
cause GI symptoms, and a lack of symptoms might lead to
non-adherence to gastroprotective agents due to forgetfulness,
which also highlights the need for patient education.
Furthermore, Lanas et al. [45] reported that short-term
treatment and adverse events were associated with poor
adherence to preventive strategies. Because PPI and H2RA
have been proved to be effective for preventing GI symp-
toms as adverse events due to NSAIDs/LDA, antisecretory
therapy might help to improve the rate of adherence to
NSAIDs/LDA, and might provide a better quality of life
via pain control and prevention of thrombosis.
Another strategy to increase the adherence rate is to use
drugs in fixed-dose combination. Several drugs including
diclofenac/misoprostol, naproxen/lansoprazole, naproxen/
esomeprazole, ibuprofen/high-dose famotidine, and LDA/
esomeprazole have been developed [46–48].
Changing pattern of GI events associated
with NSAIDs/LDA
A decline (from 1.5 to 0.5 %) in the rate of GI-related
hospitalization from 1992 to 2000 was reported for
rheumatoid arthritis patients in the USA [49]. A similar
result showing a decline (from 2.1 to 1.2 %) in the rate of
GI events was observed in a prospective observational
study conducted in the Netherlands [50]. In addition, in a
population-based study of patients hospitalized because of
GI complications in 10 hospitals between 1996 and 2005 in
Spain, a clear decreasing trend in upper-GI events and a
significant increase in lower-GI events were demonstrated
[51]. These trends over time appear to be associated with
stricter adherence to preventive strategies for NSAID-
induced GI injuries.
Casado Arroyo et al. conducted a prospective observa-
tional cohort study on the incidence of GI bleeding in
patients on dual antiplatelet therapy who were receiving
PPI co-therapy. They reported that lower-GI bleeding
occurred more frequently than upper-GI bleeding (74 %
lower vs. 26 % upper), and that this changing pattern of
bleeding might reflect the success of gastroprotection [52].
Recently, a novel composite endpoint to evaluate the GI
effects of NSAIDs through the entire GI tract, namely,
clinically significant upper- and lower-GI events (CSUL-
GIE), has been developed by a team of experts [53]. In the
CONDOR trial, in which CSULGIE was used as the pri-
mary endpoint for evaluation of the GI effects of celecoxib
or diclofenac plus omeprazole, 20 (0.9 %, upper GI: 8,
lower GI: 12) patients receiving celecoxib and 81 (3.8 %,
upper GI: 24, lower GI: 57) patients receiving diclofenac
plus omeprazole met the criteria for the primary endpoint
in a 6-month treatment period (HR 4.3, 95 % CI 2.6–7.0),
indicating that lower-GI events occurred more frequently
than upper-GI events, and that the risk of GI events asso-
ciated with celecoxib was significantly lower than that
associated with diclofenac plus omeprazole [54]. In addi-
tion, clinically significant anemia (hemoglobin drop C2 g/
dL and/or hematocrit drop C10 %) was reported to be the
most frequent event associated with NSAID-induced
lower-GI injuries [54].
Conclusions and perspectives
The efficacy of gastroprotective agents including PPIs for
NSAID-induced peptic ulcers has been proved in RCT, and
preventive strategies for safe prescription of NSAIDs are
outlined in several guidelines. The rate of adherence to
preventive strategies was reported to be low in typical
practice, but has been increasing recently. Observational
studies demonstrated that there is an inverse relationship
between adherence to PPI therapy and the risk of upper-GI
events in NSAID users. In addition, it is reported that both
the risk of hospitalization due to upper-GI events and the
medical cost are lower in NSAID users receiving PPI
therapy than in those without PPI therapy.
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Because all NSAIDs are associated with CV-related
risk, recent guidelines for the prescription of NSAIDs
require patient assessments of both GI risks and CV risks
when making appropriate choices of NSAIDs and gastro-
protective agents. However, the assessments of CV risk and
stratified GI risk are not fully implemented in routine
clinical practice.
The efficacy of antisecretory drugs for LDA-induced
peptic ulcers has also been proved in RCT. PPI therapy is
recommended for the prevention of LDA-induced peptic
ulcers in at-risk groups, and is reported to be associated
with lower risks of upper-GI bleeding and hospitalization
due to GI complications.
Furthermore, as gastroprotection spreads, the bleeding
pattern due to NSAID/LDA-induced GI injuries appears to
be changing from upper GI to lower GI. Further studies to
identify the risk factors for NSAID/LDA-induced lower-GI
injuries are required. As for the safe prescription of
NSAIDs/LDA, preventive strategies for lower-GI risk are
also required, in addition to CV risk and upper-GI risk.
In Japan, the preventive strategies upon the prescription
of NSAIDs/LDA are expected to spread rapidly because
the use of proton pump inhibitors for the prevention of
recurrence of NSAID- or LDA-induced peptic ulcers and
the use of COX-2 for the palliation of acute pain were
recently approved under the national health insurance
system. Further studies on the adherence to preventive
strategies and the outcomes of adherence, which include
both GI events and CV events, in the Japanese population
are required.
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